Mattia Algeri

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 99 publications

HLA-Haploidentical Anti-CD7 Chimeric Antigen Receptor (CAR) T Cells for Transplant-Naïve Patients With Refractory T-Cell Acute Lymphoblastic Leukemia.

HLA-Haploidentical Anti-CD7 Chimeric Antigen Receptor (CAR) T Cells for Transplant-Naïve Patients With Refractory T-Cell Acute Lymphoblastic Leukemia.

Journal: American journal of hematology
Published: July 08, 2026

2026 Update on Clinical Trials in β-Thalassemia.

2026 Update on Clinical Trials in β-Thalassemia.

Journal: American journal of hematology
Published: June 11, 2026

Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease.

Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease.

Journal: The New England journal of medicine
Published: June 11, 2026

Conditioning regimen for hematopoietic cell transplant in transfusion dependent thalassemia: Recommendations from the EBMT practice harmonisation and guidelines committee.

Conditioning regimen for hematopoietic cell transplant in transfusion dependent thalassemia: Recommendations from the EBMT practice harmonisation and guidelines committee.

Journal: Bone marrow transplantation
Published: May 27, 2026

Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia.

Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia.

Journal: American journal of hematology
Published: May 14, 2026

Second Allogeneic Hematopoietic Cell Transplantation After Graft Failure Is an Effective Curative Option in Children With Hemoglobinopathies.

Second Allogeneic Hematopoietic Cell Transplantation After Graft Failure Is an Effective Curative Option in Children With Hemoglobinopathies.

Journal: American journal of hematology
Published: January 21, 2026

Refining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.

Refining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.

Journal: Blood advances
Published: November 19, 2025

Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study.

Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study.

Journal: Blood advances
Published: November 19, 2025

Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed/refractory acute myeloid leukemia.

Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed/refractory acute myeloid leukemia.

Journal: Blood
Published: November 03, 2025

Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil.

Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil.

Journal: Haematologica
Published: September 29, 2025

Publisher Correction: GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.

Publisher Correction: GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.

Journal: Nature medicine
Published: September 09, 2025

Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.

Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.

Journal: American journal of hematology
Published: August 22, 2025
Showing 1-12 of 99

Last Updated: 09/26/2026